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Introduction
Varicella is an acute, highly contagious viral disease with 
worldwide distribution. Mostly a mild disorder in childhood, 
varicella develops with a more prolonged course, and more 
severe complications and more disabling symptoms in adults.1,2 
Therefore, the severity of varicella hospitalizations increases with 
age. The most frequent complications are skin and soft tissue 
superinfections, followed by neurological and pulmonary com-
plications. Varicella disease may be fatal, especially in neonates 
and in immunocompromized persons. In the United States of 
America, prior to availability of varicella vaccines, about 4 million 
cases of varicella occurred each year from 1990 to 1994. Of these 
cases, approximately 10 000 required hospitalization. From a 
public opinion point of view, varicella is not commonly perceived 
as an important public health problem, but the socioeconomic 
consequences, in terms of disease burden and costs of hospitaliza-
tion in industrialized countries should not be underestimated.3,4
Varicella vaccines
Monovalent and combined varicella vaccines are highly 
immunogenic and efficacious in preventing varicella disease. 
Efficacy is very high against severe varicella.5,6
A two-dose vaccination regimen results in higher serocon-
version rates and vaccine efficacy. A second dose given 4–12 
wk after primary immunization elicits comparable antibody 
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In Italy, the introduction of Universal Varicella Vaccination (UVV) has been decided but postponed, as a national pro-
gramme, until 2015, when data from Regions which have already implemented it will be available. starting from 2003, 
eight Italian Regions (Basilicata, calabria, Friuli Venezia Giulia, apulia, sardinia, sicily, Tuscany and Veneto) have progres-
sively introduced UVV, in their immunization programme, with different schedules in children aged 13–15 months and 
5–6 years, currently a two-dose schedule is adopted by all Regions. In June 2013, an Interregional Group on Varicella Vac-
cination (IGVV) has been established in order to assess the effectiveness of varicella vaccination with standardized and 
shared tools. The aim of this study was to evaluate the impact of varicella vaccination on the incidence and hospitaliza-
tions due to varicella and its complications in the period 2003–2012 in order to support the Italian decision makers on the 
future national adoption. Preliminary data showed that a general reduction of incidence and hospitalization rates was 
observed in the study period, resulting in relevant savings for the National health service. Immunization coverage with 
first dose at 24 months of age was high in all Regions (84%–95%) in 2012. adverse events due to varicella vaccines were 
rare and without permanent sequelae. Underreporting of varicella cases and delays in the administration of the first dose 
of varicella vaccines were the main critical issues. In conclusion, solid evidences in support of universal UVV arise from 
the experiences available today in Italy.
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responses to those following administration of a second dose at 
3–6 y, however the optimal timing of the second dose is still 
under discussion. A recent study by Bonanni et al. suggests that 
a short interval between two doses might be preferable for reduc-
ing breakthrough varicella (BV).7 Some other open issues remain 
concerning the persistence of immunity, the risk of complications 
in BV cases many years after vaccination,8 the requirement and 
optimal scheduling for additional booster doses or the effects of 
varicella vaccination in the long-term (e.g., transfer of maternal 
antibodies to newborns from varicella-vaccinated mothers).
Varicella vaccination policy against varicella in European 
countries
With regard to varicella vaccination recommendations in EU/
EEA countries, as of 2012 only five countries endorsed Universal 
Varicella Vaccination (UVV) for children at national level 
(Cyprus, Germany, Greece, Latvia, Luxemburg) and two coun-
tries at regional level (Spain, Italy).9
In Italy, since the approval of the National Health Plan 2003–
2005, it was recognized that the availability of effective vaccines 
against varicella allowed the start of preventive vaccination initia-
tives aimed at reducing the incidence of this important disease.10 
In the National Plan for Vaccination 2005–2007, varicella vac-
cination was recommended for persons at high risk of compli-
cations (contacts of immunocompromized subjects; health care 
workers (HCWs); childbearing age women; school personnel) 
and susceptible adolescents. UVV was only limited to Regions 
with specific vaccination programmes: in order to avoid a pos-
sible shift of infection towards adulthood, only Regions likely to 
guarantee a level of Vaccination Coverage (VC) over 80%, were 
recommended to introduce varicella vaccination.11
To date, the introduction of UVV has been decided but post-
poned, as a national programme, until 2015, when data from 
Regions which already implemented it will be available. At the 
national level, varicella vaccination was recommended in adoles-
cents not previously vaccinated and anamnestically negative for 
varicella infection, in particular the administration of two doses 
one month apart from each other is suggested.12
In Italy, only eight Regions, out of 21, started a UVV pro-
gramme at the time of our data collection: Apulia, Basilicata, 
Calabria, Friuli Venezia Giulia, Sardinia, Sicily, Tuscany, and 
Veneto.13-20
The population belonging to those eight Regions amounted 
to almost 23 Million people, about 40% of the Italian resident 
population in 2012.21
In June 2013, an Interregional Group on Varicella Vaccination 
(IGVV) was spontaneously established with the aim to share epi-
demiological data to measure the impact of the UVV programmes 
started in the above mentioned Italian Regions. The aim of the 
IGVV is to provide and spread regional and aggregated data 
within the scientific community and institutions; to exchange 
experiences on the varicella vaccination; to compare vaccination 
schedules and strategies adopted; above all, to provide additional 
elements for the assessment of the epidemiological impact of the 
UVV programmes in order to support the Italian decision mak-
ers on the future national adoption.
The specific aims of this study were to show the impact of 
UVV programmes on varicella incidence trends and on hospi-
talizations due to varicella complications and to assess the total 
annual costs of hospitalization due to varicella in eight Italian 
Regions, in the period 2003–2012. Furthermore, vaccination 
coverage data and available adverse event reporting rates follow-
ing varicella vaccinations, were also provided.
Results
Starting from 2003, the Italian Regions of Apulia, Basilicata, 
Calabria, Friuli Venezia Giulia, Sardinia, Sicily, Tuscany, and 
Veneto, have progressively introduced UVV, in their immuni-
zation programme, with different schedules in children aged 
13–15 mo and 5–6 y. Currently, a two-dose regimen for varicella 
vaccination is implemented in the 8 Regions. In these Regions 
varicella vaccination was universally offered free of charge. Some 
differences could be found in the schedules adopted by the 8 
Italian Regions. (Table 1)
Since the introduction of UVV programme in each Region, 
a decrease in incidence rates has been observed. In Figure 1 
varicella Regional incidence rates are reported comparing the 
relative time (in years) before and after the UVV programme 
introduction, corresponding to the time “zero”, in each Region. 
The reduction of varicella incidence was higher in Regions which 
started the programme earlier, namely in Sicily, Veneto, Apulia, 
and Tuscany. In those Regions the decrease of varicella incidence 
was almost linear, since the time “zero” onward. However, even 
in Basilicata and Calabria, the positive effect of the immuniza-
tion programme is measurable after only two years of varicella 
vaccination introduction. On the other hand, in Sardinia and in 
Friuli Venezia Giulia, it is too early to measure a clear impact of 
UVV programme on incidence rates, because these two Regions 
implemented varicella vaccination only recently. As a matter of 
fact, in Sardinia only 6 out of 8 Local Health Units (LHUs) 
started the UVV programme, and in FVG incidence data for the 
first year of UVV introduction (2013), were not included in the 
observation period of this survey.
Reported incidence rates were higher in Regions of North and 
Central Italy (Friuli Venezia Giulia, Veneto, and Tuscany) while 
in the other Regions, belonging to Southern and insular areas, 
reported incidence rates were lower, possibly reflecting varying 
under-notification rates in the different areas of the country.
In Figure 2, aggregated data obtained summing up all vari-
cella official notifications reported in the 8 Regions are shown. 
Besides, incidence rates and 95% CI were also calculated for each 
year from 2003 to 2012. A downward trend in incidence rates is 
clearly observed in the entire period of observation. The highest 
incidence rate was observed in 2004 when only Sicily Region had 
already implemented the UVV programme. From 2006 onward, 
in the IGVV Regions, the incidence rates decreased constantly 
up to 2012, when varicella incidence rate reached the lowest 
annual level of all the period.
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Moreover, based on the most recent estimates provided by the 
Italian sentinel networks of primary care pediatricians (SPES, 
Sentinel Pediatric Surveillance), we have assumed an average 
varicella underreporting rate of 5 for mandatory notification for 
the whole period and for all age groups.22,23 (Fig. 2)
As far as age specific incidence rates are concerned, all Regions 
reported the highest percentages of notifications in individuals 
under 15 y of age. In those age groups, percentages of varicella 
notifications varied between Regions but were >80% of the over-
all notified cases in all of them (data not shown).
The number of hospitalizations due to varicella complications 
is underestimated in our study with a high likelihood because 
some Regions did not provide data for the entire period (Tuscany 
in 2003 and Calabria in 2003 and 2004). However, the reduc-
tion of hospitalizations, and therefore of the hospitalization rates, 
from 2004 to 2012 was almost 75%. (Fig. 3)
All these hospitalizations accounted for a high total cost in 
Euro. The total annual costs of hospitalizations due to varicella in 
6 of the 8 Italian Regions, as primary and secondary diagnoses, 
are presented in Figure 4. An almost linear decrease trend was reg-
istered after the UVV implementation. Indeed, costs of hospital-
izations are underestimated since for two Regions (Sardinia and 
Calabria) data were not available for the entire period. Moreover, 
for two other Regions (Tuscany and Veneto) data were not 
Table 1. Year of Universal Varicella Vaccination introduction and schedules adopted in 8 Italian Regions
Region
Year of 
introduction
13° mo 14° mo 15° mo 24° mo 5 y 6 y 11 y 12 y 14 y 15 y 18 y
Sicily 2003
MMRV 
or 
MMR+V- 
MeN c
MMRV or 
MMR+V - 
DTaP-IPV
V
Veneto 2005 MMRV PcV
MMRV – 
DTaP-IPV 
– MeN c
V
Apulia 2006 MMRV - ha MeN c
ha 2° 
dose
MMRV - DTaP-IPV MMRV - MeN c
Tuscany 2008 MMRV or MMR+V - MeN c MMRV - DTaP-IPV V
Basilicata 2010
MMRV 
-MeN c
MMRV - 
DTaP-IPV
Calabria 2010 MMRV o MMR+V - MeN c
MMRV or MMR+V 
- DTaP-IPV
MMRV o MMR+V
Sardinia 2011
MMRV or 
MMR+V
MMRV
Friuli 
Venezia 
Giulia
2013
MMRV 
- PcV13
MMRV -
DTaP-IPV
Figure 1. Varicella incidence rates (×1000) in 8 Italian Regions, before and after the time “zero” of Universal Varicella Vaccination introduction (time 
“zero” being the year of start of varicella vaccination implementation, which is different in the different Regions).
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available for the first year (2003). However, considering available 
data, a decreasing trend could be observed in the costs sustained 
by the Regional Health Service in the period of observation. In 
2012, the annual costs settled to a value under 1 Million Euro, 
more than a half less of the value reported in 2004, when only 
Sicily Region had already implemented UVV. Comparing total 
annual hospitalization costs in 2004 and 2012, a general reduc-
tion of 60% was observed. Higher percentages of costs reduction 
were observed in Apulia (86%), Sicily (83%), Tuscany (77%), 
Veneto (75%), and Basilicata (71%), while in Friuli Venezia 
Giulia the reduction was modest, only 10%, because it was the 
last Region implementing a UVV programme.
Immunization coverage with varicella vaccines at 24 mo of 
age reached high levels in 2012 in all Italian Regions. The highest 
VC levels were registered in Apulia and Basilicata (over 90%); in 
Tuscany, Veneto and Sicily VC settled between 84% and 88%, 
while for Sardinia and Calabria only incomplete data were avail-
able. Data on VC in 2 out of 8 LHUs of Sardinia were available 
Figure 3. hospitalizations and annual hospitalization rates due to varicella complications (×100 000) in 8 Italian Regions (2003–2012). [Tuscany: data not 
available for 2003; calabria: data not available for 2003 and 2004] (Note: 95% cI for hospitalization rates are reported in square brackets).
Figure 2. Varicella notifications, incidence rates and estimated incidence rates, assuming a 5-fold underreporting rate in the IGVV Regions (2003–2012). 
(Note: 95% cI for estimated incidence rates are reported in square brackets).
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and settled at 72% and 82% in the LHU of Sassari and LHU 
of Cagliari, respectively. Finally, the UVV programme started 
in Friuli Venezia Giulia Region between March and April 2013, 
therefore, data on immunization coverage will be only available 
from 2015. As far as VC in Friuli Venezia Giulia is concerned, in 
Table 2 only compliance to vaccination for the birth cohort 2012 
was available and updated on April 29, 2014. 
Some Regions provided also data on adverse events following 
varicella immunization (AEFI) for the calculation of the adverse 
events reporting rate. (Table 3) Veneto reported the highest rates 
in the entire period and Apulia the lowest. In Veneto, an active 
network of pharmacovigilance for monitoring vaccination safety 
was available since 1993.
Discussion
In Italy, during the last decade, Regions adopted different 
policies for vaccines not universally recommended at the national 
level. In particular, recommendations on varicella vaccination 
were heterogeneous and led to a marked discrepancy in vaccina-
tion coverage observed through the country.
The results of three surveys promoted by the Italian National 
Institute of Health (ISS) showed that Regions changed their rec-
ommendations between 2006 and 2010. In 2010, 7 Regions had 
adopted a UVV programme targeting children and susceptible 
adolescents. The remaining Regions offered varicella vaccination 
free of charge only to specific risk groups (such as child-bearing 
age women, health and school workers, household of individuals 
with immunodeficiency, chronic renal failure, HIV infection).24
According to the results of the current study, the impact of 
a UVV programme on incidence rates was higher in Regions 
which started the programme earlier, i.e., Sicily, Veneto, Apulia, 
and Tuscany. In those Regions, an almost linear trend of varicella 
incidence decrease was observed, since the year “zero” of UVV 
introduction and up to 2012.
Sicily has been the first Italian Region to adopt in 2003 a one-
dose UVV programme, with a coverage that, in a first period, 
ranged from 40% in 2003 to 60.5% in 2005. Both the initial 
suboptimal vaccine coverage and the one-dose strategy could 
explain the relatively slight decline in varicella morbidity that we 
have observed in the first years after the immunization intro-
duction. Conversely, since 2007 vaccination coverage increased 
to 70% with a significant reduction of attributable morbid-
ity that, as reported by other authors, in subjects under 15 y, 
passed from 95.7 to 9 cases/1000 person year. Accordingly, an 
important decrease in hospitalization due to varicella with com-
plications (75% less) and without complications (80% less) was 
also observed.25,26 From 2010, the schedule was changed into a 
two-dose scheme and varicella immunization coverage increased 
steadily above 80%, being associated with a further reduction of 
varicella incidence to less than 0.1 cases/1000 person year.
In Veneto, a rapid implementation of the UVV programme 
allowed a drastic reduction of varicella incidence in all age 
groups. In 2004, there were about 60 600 new cases of varicella in 
Veneto, while the estimated number in 2008 dropped to 23 600 
with an estimate of about 37 000 prevented cases. VC increased 
from 68% in 2006 to 79% in 2010. Hospitalization rates in 
Veneto decreased from 18.7/100 000 in 2000 to 8.4/100 000 in 
2008.27,28 According to the results provided within this study, in 
Veneto in 2012 the VC at 24 mo increased again reaching values 
close to 90% (87.8%), and the decreasing trend in hospitaliza-
tion rates continued until 2012, when it dropped to 0.8/100 000.
Since 2006, in Apulia, a decrease in incidence rates based on 
official notifications was observed, passing from 4500 varicella 
cases in 2006 to about 230 cases in 2012, corresponding to inci-
dence rates of 1.1/1000 and 0.56/1000, respectively in 2006 and 
2012. Even hospitalization rates decreased in the entire period 
Figure 4. Total annual costs of hospitalizations due to varicella, as primary and secondary diagnoses, in 6 Italian Regions (2003–2012) (Tuscany and 
Veneto: data not available for 2003; sardinia and calabria: data not available for the entire period).
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of observation. All these results can be surely attributed to the 
high VC for varicella vaccines at 24 mo, that in 2012 reached 
91.1%. Moreover, in Apulia, data on VC at 5–6 y of age and at 
15 y were also provided. In 2012, VC for varicella reached the 
value of 64.8% and 28.8% for the birth cohorts 2005 and 1997, 
respectively.
In Tuscany VC at 24 mo for varicella reached 75% in 2010 
and 84% in 2012. A reduction in notifications of 60% after 
four years of UVV implementation was observed. Therefore, 
the average incidence for varicella halved passing from a value of 
2.3/1000 before varicella introduction (2004–2007) to a value 
of 1/1000 inhabitants in the vaccination period (2009–2012). 
The reduction of cases was observed in all age groups. After the 
introduction of the UVV programme in Tuscany, even hospital-
izations and costs due to hospitalization for varicella decreased 
rapidly. Moreover, two further results were observed in Tuscany; 
a reduction in the severity of varicella complications because 
cases of post-varicella encephalitis halved in the vaccination 
period, and the number of haemorrhagic pneumonia due to vari-
cella decreased to one fifth, besides an increase in the appropri-
ateness of hospital admissions was also observed, due to decrease 
of varicella uncomplicated cases hospitalized.29,30
In Basilicata, VC at 24 mo for varicella reached the objective 
of 95% already in 2012. Therefore, incidence and hospitalization 
rates decreased already two years after UVV introduction, and 
the number of encephalitis cases due to varicella dropped to zero 
in the two-year vaccination period.
In the first year of UVV introduction in Calabria (2010), 
the adherence to varicella vaccination was 71%, but a decline 
in varicella vaccination compliance in a LHU of Calabria was 
observed the following year (55% in the birth cohort 2011). The 
recommendation from the National Drug Agency (AIFA) in 
November 201131 stating that the quadrivalent MMRV vaccine 
should no longer be recommended for the first dose administra-
tion resulted in an initial confusion of both parents and health 
care workers (hygienists and pediatricians) which resulted in a 
decreased adherence to vaccination. Fortunately, the problem 
was overcome through the application of a model of vaccination 
counseling involving most parents on the choice of the quadriva-
lent or monovalent vaccine since the first dose. In Calabria, the 
main concern regards the lack of activation of a computerized 
registry for vaccination, making it extremely difficult to monitor 
vaccine supply and to recall subjects for the first dose as well as 
for the second dose.
In Sardinia, 13 000–16 000 cases of varicella were estimated 
each year, among them 10 000 cases occurred in pediatric age. 
Besides, varicella can present with complications in 3.5% of 
healthy children under 15 y of age.32 A clear impact on varicella 
incidence and hospitalization rates could not be observed in our 
study, because of the very recent introduction of UVV. Moreover, 
at the end of 2011, as a consequence of AIFA recommendation32 
the MMRV vaccine was no longer recommended as first dose in 
most of LHUs and a decrease in VC was temporarily observed. 
Only in the LHU of Cagliari the programme was started and 
actively continued with MMRV as first dose.
In Friuli Venezia Giulia, 4000 varicella cases were annu-
ally registered and 20–40 hospitalizations due to varicella can 
be observed annually. The incidence rate for varicella in 2012 
was 3.4/1000 inhabitants, and the hospitalization rate was 
2.1/100 000 inhabitants. Having introduced only recently a 
UVV, Friuli Venezia Giulia can be considered epidemiologically 
similar to a Region without vaccination.
The results of our study showed a decrease in costs of hospi-
talization due to varicella in the period of observation. Since a 
change in the system of attribution of hospitalization codes did 
not occur during the study period, such clear decreasing trend 
is attributable to an increase in the use of varicella vaccines. 
Moreover, hospitalization costs are probably underestimated, 
mainly because not all the 8 Regions collected data for the entire 
period. Second, a certain degree of underestimation in hospi-
talization costs, based on DRG, was already assessed in Italy by 
Azzari et al.33 In addition, in the same study by Azzari et al., 
the highest rate of hospitalization (85.1%) was found in children 
<4 y of age and the largest number of complications (87.2%) 
occurred in previously healthy children. Considering that >85% 
of varicella cases occurred in subjects under 15 y, who are the 
main target of varicella vaccination, all Italian children and ado-
lescents could receive a great benefit from UVV introduction at 
the national level because varicella vaccines have already demon-
strated to protect from infection and from severe complications.
The persistence of varicella hospitalizations in the 8 Regions 
indicates the presence of a greater number of cases than those 
reported, and the need to better quantify the degree of under-
notification, especially in some areas of the country.
Table 3. Reporting rate of adverse events following varicella immunization 
(aeFI) in 4 Italian Regions (2003–2012) [Data not available for calabria, Friuli 
Venezia Giulia, sardinia, sicily]
Period of 
observation
average ae reporting 
rate (ae/10,000 
administered dose)
annual range
(aeFI/10,000 
administered dose)
apulia 2006–2012 1.8 [0.5 – 7.4]
Basilicata 2010–2013 2.3 [0.0 - 4.7]
Tuscany 2005–2011 5.4 [2.1 – 8.8]
Veneto 2003–2012 14.9 [6.3 – 23.7]
Table 2. Vaccination coverage for varicella vaccination at 24° months in 8 
Italian Regions (2010 cohort), in 2012
Vc 24 mo
apulia 91.1%
Basilicata 95%
calabria 77% LhU of Reggio calabria
Friuli Venezia Giulia
Birth cohort 2012: 60%  
(Update on april 29, 2014)
Tuscany 84%
sardinia 72% LhU of sassari; 82% LhU of cagliari
sicily 84.5%
Veneto 87.8%
www.landesbioscience.com human Vaccines & Immunotherapeutics 7
In 1976–96, the degree of underreporting in Italy was esti-
mated to be 7.7: approximately only 1 case of varicella out of 8 
was notified in subjects between 6 m–20 y. Differences in under-
reporting rates were found between North, Centre, and South 
areas. Our results could likely reflect the degree of under-notifi-
cation rates in the different areas of the country. For highly infec-
tious diseases, like varicella, nearly all individuals will have been 
infected before adulthood, and, assuming a stable population, the 
number of births roughly corresponds to the number of cases. In 
Italy, during the second half of the Nineties, the average annual 
number of notified varicella cases was approximately 100 000 
while the number of births in the same period was over 500 000 
accounting for an underreporting ratio close to 5.23
Our results are consistent with these estimates, in fact, consid-
ering the number of official varicella notifications in 2004 (when 
only Sicily had implemented UVV and all the 8 Italian Regions 
provided notification data), after the application of an underre-
porting factor of 5 to data collected in this study, the estimated 
number of varicella notifications reached a value close to 250 000 
cases, a bit less than a half of a birth cohort of Italian popula-
tion. Considering that the resident population in the 8 Regions 
participating to this study is near to 40% of the national popula-
tion, a correspondence between our estimates and those already 
published can be found.
As a matter of fact, UVV programmes started in the 8 Italian 
Regions are likely to have prevented a number of cases almost 
5-fold higher than that provided by official varicella notifications.
In Italy, a certain concern was raised on varicella vaccines, and 
in particular on the use of the MMRV vaccine after recommen-
dations from the advisory vaccination committees in USA and 
Germany, and from the Italian Ministry of Health of preference 
for the use of monovalent vaccines for the first dose.34,35 In this 
study, a decrease of VC in specific areas was observed as a conse-
quence of such recommendations.
Although the objectives set by the regional plans for VC have 
not yet been achieved, the use of the tetravalent MMRV vaccine 
has contributed substantially to the improvement of vaccine cov-
erage, in some Regions (data not showed). The administration of 
varicella vaccine in the same vaccinating session of MMR, or bet-
ter, the use of the quadrivalent MMRV vaccine avoids the delays 
of varicella immunization connected with the need to separate 
vaccination sessions when more than 3 injections should be given 
at the same time. Considering the delay for V vaccination, it 
might be useful to register routinary VC also at 36 mo of age (as 
in Veneto Region). In addition, registration of VC for the second 
dose at 6 y and in the adolescence at 16 y for 1st and 2nd dose 
should be introduced.
A limitation of our study is implied in the fact that the 8 
Italian Regions adopted a UVV programme with different sched-
ules and in different years, and therefore the periods before and 
after UVV introduction are different in length. Besides, collec-
tion of data was not completed for the entire period by all the 8 
Regions, likely leading to an underestimation of the real burden 
of disease, especially concerning hospitalization. Furthermore, 
the information collected in this study does not allow to describe 
the post-marketing safety profile of the combination vaccine 
MMRV, with particular reference to the uncertainties on the 
increased risk of developing febrile seizures. More exhaustive 
investigations should be performed in order to assess the problem 
of the adverse events following varicella immunization for which 
in this analysis only a crude AEFI reporting rate was calculated 
from data obtained by half of the Regions included in this study.
Conclusion
A general reduction of incidence and hospitalization rates in 
all Regions after the UVV introduction is evident in our study. 
Despite mandatory varicella notification, likely underreporting 
in Italy continues to be high. A more sensitive surveillance system 
could reduce the degree of underreporting. Sentinel surveillance 
systems, such as the now discontinued pediatric surveillance net-
work SPES, are more precise but their implementation is difficult 
and expensive.
Economic savings for the National Health Service, in terms 
of hospitalization reductions, were relevant but they are under-
estimated. In 2012, high varicella vaccination coverage rates at 
24 mo were observed in all 8 Italian Regions. Adverse events due 
to MMRV (Measles-Mumps-Rubella-Varicella) vaccine were 
rare and without permanent sequelae, nevertheless, monitoring 
of varicella vaccination safety through an active pharmacovigi-
lance system is necessary in order to increase the compliance to 
vaccination in the population.
Solid evidences in support of UVV arise from the experiences 
of the 8 Italian Regions where data are accumulating and/or are 
available to support the positive impact of UVV programmes.
The hope is that, in 2015, active free-of-charge UVV will be 
confirmed for all Italian children.
In such perspective, the MMRV vaccine is an essential tool, 
providing an organizational simplification and a reduction of 
accesses to immunization services.
Italian Regions are ready to implement a surveillance system 
including all the key elements suggested by ECDC. According to 
ECDC recommendations, the strategic elements to survey vari-
cella epidemiology should be the monitoring of vaccine coverage, 
vaccine effectiveness, the occurrence of AEFI, the availability of 
age-specific disease incidence for varicella and age-specific inci-
dence of severe disease (i.e., needing hospitalization). Surveillance 
for zoster is also needed to assess the impact of varicella vaccina-
tion on herpes zoster (HZ) and Italian Regions are moving for-
ward to close the gap of knowledge in this field, too.9,36 Results 
provided by the IGVV members represent a further tool available 
for decision makers to assess the effectiveness of the UVV pro-
gramme and to encourage (with data “on field”) the extension of 
universal varicella vaccination nationwide.
Materials and Methods
Members of the IGVV adopted a methodology for data col-
lection from the regional archives of each participating Region. 
A common tool for data collection was delivered to all IGVV 
members on December 2013, in order to collect the same epi-
demiological data in the period 2003–2012. In particular, each 
participant was invited to fill in some work sheets produced in 
8 human Vaccines & Immunotherapeutics Volume 11 Issue 1
advance to automatically calculate: incidence rates based on vari-
cella mandatory notifications, by year and by age group; hospi-
talization rates of complications due to varicella; the total costs 
of hospitalization due to varicella or its complications, as pri-
mary and secondary diagnoses; adverse events following varicella 
immunization. Moreover, vaccination coverages (VC) at 24 mo 
of age were also provided by IGVV members.
Incidence data
Varicella is subject to mandatory notification in Italy, and data 
provided by IGVV members were routinely collected at Regional 
level and reported to the Italian infectious diseases surveillance 
system.37 Data on mandatory notifications, for the calculation 
of the incidence rates, were collected from all 8 Regions in the 
whole period (excluding Tuscany in 2003). Incidence rates were 
presented separately, by Region and as aggregated data, summing 
up all varicella notifications reported in the 8 Regions. Incidence 
rates are reported comparing the relative time (in years) before 
and after the UVV programme introduction, corresponding to 
the time “zero”, in each Region. Moreover, the number of esti-
mated notifications was calculated applying an underreporting 
factor of 5 to all official notifications, in order to calculate a pos-
sible and probably more realistic scenario of varicella burden of 
disease. This is probably a conservative figure because in differ-
ent age groups and geographic areas the underreporting factor 
could be higher, especially in older subjects and in the Southern 
Regions of Italy.22,23 95% CI for incidence rates were calculated 
for each year from 2003 to 2012.
Hospitalization data
Hospitalization data, covering the period 2003–2012, were 
collected by IGVV members of the 8 Regions, and all hospi-
talized cases for varicella or its complications, as a primary or 
secondary discharge diagnosis, were examined. In particular all 
hospital discharge records with the ICD9-CM code 052 (052.0, 
post-varicella encephalitis; 052.1: haemorragic pneumonia due 
to varicella; 052.2, myelitis post-varicella; 052.7, varicella with 
other specified complications; 052.8, varicella with other com-
plications not specified; 052.9, varicella without mention of com-
plication) were included in the analysis. 95% CI were calculated 
for hospitalization rates for each year from 2003 to 2012. Annual 
hospitalization rates were calculated on the resident population 
of the 8 Regions.21
Costs of hospitalization
In Italy, hospital discharge records represents the regional 
reimbursement document for the hospitals or health facilities, 
thus each hospitalization is associated with a cost, based on DRG 
(Diagnosis Related Groups), which is covered by the Regional/
National Health Service. Costs of hospitalization due to varicella 
(ICD9-CM code 052) were collected in the period 2003–2012. 
Data on costs of hospitalization were collected only from 6 out 
of 8 Regions in the whole period. Sardinia and Calabria did not 
provide data on costs of hospitalization while for Tuscany and 
Veneto data for 2003 were not available.
Vaccination coverage
Each IGVV member provided data on available VC at 24 mo 
for all the available years since UVV introduction.
Adverse events following immunization
Adverse events following varicella vaccines were collected from 
the national pharmacovigilance system and a crude AEFI report-
ing rate was calculated on the number of administered varicella 
vaccine doses, by year.
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